Cost-Effectiveness of Adolescent Pertussis Vaccination for The Netherlands: Using an Individual-Based Dynamic Model by de Vries, Robin et al.
Cost-Effectiveness of Adolescent Pertussis Vaccination
for The Netherlands: Using an Individual-Based Dynamic
Model
Robin de Vries
1*, Mirjam Kretzschmar
2,3, Joop F. P. Schellekens
4, Florens G. A. Versteegh
5, Tjalke A.
Westra
1, John J. Roord
6, Maarten J. Postma
1
1Unit of Pharmacoepidemiology and Pharmacoeconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands, 2Centre for Infectious
Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands, 3Julius Centre for Health Sciences and Primary Care,
University Medical Centre Utrecht, Utrecht, The Netherlands, 4Laboratory for Infectious Diseases, Groningen, The Netherlands, 5Department of Pediatrics, Groene Hart
Ziekenhuis, Gouda, The Netherlands, 6Department of Pediatrics, VU University Medical Center, Amsterdam, The Netherlands
Abstract
Background: Despite widespread immunization programs, a clear increase in pertussis incidence is apparent in many
developed countries during the last decades. Consequently, additional immunization strategies are considered to reduce
the burden of disease. The aim of this study is to design an individual-based stochastic dynamic framework to model
pertussis transmission in the population in order to predict the epidemiologic and economic consequences of the
implementation of universal booster vaccination programs. Using this framework, we estimate the cost-effectiveness of
universal adolescent pertussis booster vaccination at the age of 12 years in the Netherlands.
Methods/Principal Findings: We designed a discrete event simulation (DES) model to predict the epidemiological and
economic consequences of implementing universal adolescent booster vaccination. We used national age-specific
notification data over the period 1996–2000—corrected for underreporting—to calibrate the model assuming a steady
state situation. Subsequently, booster vaccination was introduced. Input parameters of the model were derived from
literature, national data sources (e.g. costing data, incidence and hospitalization data) and expert opinions. As there is no
consensus on the duration of immunity acquired by natural infection, we considered two scenarios for this duration of
protection (i.e. 8 and 15 years). In both scenarios, total pertussis incidence decreased as a result of adolescent vaccination.
From a societal perspective, the cost-effectiveness was estimated at J4418/QALY (range: 3205–6364 J per QALY) and
J6371/QALY (range: 4139–9549 J per QALY) for the 8- and 15-year protection scenarios, respectively. Sensitivity analyses
revealed that the outcomes are most sensitive to the quality of life weights used for pertussis disease.
Conclusions/Significance: To our knowledge we designed the first individual-based dynamic framework to model pertussis
transmission in the population. This study indicates that adolescent pertussis vaccination is likely to be a cost-effective
intervention for The Netherlands. The model is suited to investigate further pertussis booster vaccination strategies.
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Introduction
Pertussis (whooping cough) is a highly contagious infection of the
respiratory tract. It is caused by the bacteria Bordetella pertussis,a n d
occasionally, Bordetella parapertussis. Before the introduction of
vaccination programs, pertussis was a main cause of child morbidity
and mortality in developed countries. After the introduction of
routine vaccinationprograms the incidenceof pertussis decreasedto
very low levels. However, during the past decade the incidence has
again shown an increasing trend in many developed countries with
a shift in the incidence towards older age groups [1].
Despite a high vaccination coverage (<96%) a clear increase in
the incidence of pertussis was also apparent in the Netherlands from
1996 onwards [2–4]. This increase is most marked in adolescents
and adults. This is of concern as adolescents and adults have been
identified as a major source of transmission of pertussis to very
young yet unimmunized and only partly immunized infants, in
whom pertussis causes serious morbidity and mortality [5,6]. As
pertussis infections often go by unnoticed in adolescents and adults,
partly because the disease is often misdiagnosed in these age groups
by clinicians and partly as many infections remain asymptomatic,
theactualincidence inthisagegroup probablyismuchlargerdueto
underreporting [7,8]. Although pertussis is not generally recognized
as a serious problem beyond childhood, it can cause significant
morbidity and costs in adolescents and adults with productivity
losses comprising the largest costs [9,10].
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cell vaccines in many developed countries [1,11]. These acellular
vaccines are less reactogenic, improving their safety profile. In the
Netherlands, until 2001, the vaccination schedule consisted of four
doses of the whole cell pertussis vaccine (currently at 2, 3, 4
months of age and a booster vaccination at 11 months of age).
From 2001 onwards, an additional booster vaccination (acellular
vaccine) is given to four year old children to reduce the incidence.
Moreover, from 2005, the four whole cell vaccinations given
within the first year of life have been replaced by the acellular
vaccine [12].
Vaccine-induced immunity is known to be of relatively short
duration (,8 years), after either immunization with whole cell
or acellular vaccines [13,14]. Considering the fact that thus
adolescents and adults are a major reservoir for pertussis
transmission to very young infants, addition of immunization
strategies to the current childhood program to decrease the
incidence in adolescents or adults may be considered. A decrease
in the pertussis incidence in adolescents or adults may be expected
to lead to an increase in herd immunity that in turn indirectly
results in an increased protection of young vulnerable infants
[5,15]. Currently, several countries (e.g. Germany, France,
Canada, Australia) have already incorporated an adolescent
booster dose (acellular vaccine) into their immunization program
[1,16].
The main goal of this paper is to design an individual-based
stochastic dynamic framework to model the pertussis transmission
in the population in order to predict the epidemiologic and
economic consequences of the implementation of universal booster
vaccination programs. Using this framework, we currently
estimate the cost-effectiveness of universal adolescent pertussis
booster vaccination at the age of 12 years in the Netherlands.
Methods
In this section we elaborate on the individual-based dynamic
model and the data used for the cost-effectiveness analysis. In
general, the model consists of a dynamic epidemiologic part and
an economic part. In particular, the epidemiologic part can be
used for estimating the impact of an universal booster vaccination
strategy on the incidence and prevalence of pertussis in the
population. Specifically, here, it was used for estimating the
epidemiologic consequences of adolescent booster vaccination in
the Netherlands. The economic part addresses the averted
complications, associated costs and the cost analysis of the
adolescent booster vaccination. Both models were linked by using
the output of the epidemiologic part as input for the economic
analysis to estimate cost-effectiveness.
Dynamic Epidemiologic Model
We designed a discrete event simulation (DES) model to model
pertussis transmission in the population [17–19]. Contrary to
deterministic SIR (Susceptible-Infected-Recovered) models, which
are often used to model infectious diseases, within a DES-model
individual persons are modeled rather than cohorts [17–19,20].
Furthermore, a fundamental aspect of DES is time which
advances in ‘discrete’ jumps; for every individual the time until
the next event happens is determined and the simulation proceeds
along a chain of events [17–19]. A schematic representation of the
possible individual pathways within the designed pertussis DES-
model is shown in Figure 1.
We developed a model that distinguishes between three types of
infections: infections in immunologically naive individuals (i.e.
primary infections), infections in individuals whose immune system
has been primed before by vaccination or infection (i.e. recidive
infections), and asymptomatic infections (note that all primary and
recidive infections were assumed to be symptomatic). All
individuals are born susceptible after which they run the risk of
acquiring a pertussis infection after contact with an infectious
person. After infection, individuals recover and become immune.
Immunity wanes over time. We divided immunity into two types:
full immunity (i.e. immunity against infection and disease), and
partial immunity (i.e. immunity against disease only). In particular,
although a partial immune individual is able to acquire an
infection and subsequently transmit the pathogen to other
individuals in the population, the partial immune individual will
not become ill (i.e. only experiences asymptomatic infection).
Furthermore, we assumed that if a partial immune, or susceptible,
individual comes into contact with the pathogen by either
vaccination or infection, the person will become full immune
again through this next priming of the immune system. The DES-
model was built in ArenaH [21].
Model Parameters
Although the duration of the infectious period is not precisely
known and probably varies widely, it likely depends on the severity
of the disease. Based on expert opinions, we assumed that the
mean period which an individual with pertussis is infectious lasts 4
weeks for primary infected cases, 3 weeks for recidive infected
cases and 1 week for asymptomatic cases.
We assumed that childhood vaccination as well as adolescent
vaccination has influence on the level of immunity of both partial
immune and susceptible individuals. As a result of vaccination,
both groups were assumed to become immune against both
disease and infection (Figure 1). The vaccination coverage in the
Netherlands is about 96% for infants and the same was assumed
for adolescents. In the model we divided the vaccination scheme
into three parts: (i) the vaccinations at 2, 3, 4 and 11 months of
age; (ii) the booster dose at 4 years of age; and (iii) a booster in
adolescents at 12 years of age. In reality immunity after
vaccination is gradually built up after each vaccination dose
within the first year of life. However, for simplicity, with regard to
the immunization within the first year we assumed that a certain
fraction of the population (i.e. coverage6efficacy) is effectively
protected precisely after 4 months (i.e. 1 month after the second
vaccination at 3 months of age).
Before the implementation of the acellular booster vaccination
at the age of 4 years, the efficacy of the whole cell pertussis vaccine
used in the Netherlands was estimated at 89% [2,22–25]. This
estimate was based on observational data from the Netherlands, in
particular national notification reports, during the period when in
the Netherlands a locally-produced whole-cell vaccine was used
(manufacturer: National Institute of Public Health/Netherlands
Vaccine Institute). Since 2001, acellular vaccines have been
introduced in the Dutch Immunization Program, based on an
advice by the Dutch Health Council that efficacy of these vaccines
would not be inferior to those of the whole-cell vaccine and a
superior safety profile of the acellular products [26]. In particular,
5-component acellular pertussis vaccines are currently used in the
Netherlands for infants (Pediacel
(R) and Infanrix-hexa
(R)) and for
boostering at the age of 4 (Infanrix-IPV
(R)). These multi-
component ($3 components) vaccines have a higher efficacy than
one- and two-component acellular vaccines and have not been
assessed inferior to the best whole cell vaccines on a statistically
significant level [27,28]. Based on clinical trial data the efficacy of
an acellular adolescent booster vaccine for adolescents was also
estimated at a quite similar level [29–31]. Therefore, in the model
we assumed the same efficacy at 89% for vaccination within the
Pertussis Vaccination
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vaccination at 12 years of age. The duration of protection after
vaccination is discussed below (see Scenarios section).
In general, the most important term in a dynamic model would
be the so-called force of infection (FOI). The FOI denotes the rate
at which susceptible individuals acquire an infection [20]. Here we
used the method developed by van Boven et al [23] to estimate the
age-dependent FOI from age-specific incidence data. The
advantage of that method is that the estimation procedure is
based on the underlying model structure. Furthermore, it is
possible to take the waning immunity and different types of
infection consistently into account. For the estimation of the age-
specific FOI we had to assume a stable age distribution and an
endemic equilibrium (i.e. steady state). We divided the population
in 86 age classes; 74 yearly classes (1–74 years) and the first year
separated into monthly classes (0–11 months). We assumed an
endemic equilibrium from 1996 to 2000. Therefore, we averaged
the case notification data from the Netherlands over those years to
obtain the age-specific steady state incidences and prevalences
[32].
Subsequently, these numbers were corrected for underreport-
ing. Previously, de Melker et al estimated that, in the Netherlands,
the true incidence was approximately 660 times higher than the
reported incidence for children and adults [33]. We used the age
specific ratios of estimated numbers to notified numbers for
correcting the age-specific incidences [33]. We note that in reality
there probably was no endemic equilibrium from 1996 to 2000
[32], but for correctly analyzing the effects of different immuni-
zation strategies a steady state situation has to be assumed in order
to discard the time dependence in the incidence and prevalence.
The set of differential equations used for estimating the age-
specific FOI is given in Appendix S1. For a full description of the
methodology we refer to van Boven et al [23].
The FOI is a function of the number of infectious individuals at
a given point in time, the contact function and the transmission
coefficients. Here, the age specific FOI is given by:
l(a,t)~
ð ?
0
C(a,a0) b1(a)I1(a0,t)zb2(a)I2(a0,t)zb3(a)I3(a0,t) fg da0
Where I1,I 2 and I3 are the prevalences of primary infected,
recidive infected and asymptomatically infected individuals,
respectively. The contact function (C(a,a9)) is a 86686 matrix
representing the number of contacts between an individual in
age-group a with an individual in age-group a9 per unit of time.
We used the contact matrix for respiratory diseasesforthe Dutch
population estimated by Wallinga et al [34,35]. The transmis-
sion coefficient (b) represents the probability that a contact
between a susceptible individual of age a with an infectious
individual of age a9 leads to transmission. We assumed different
transmission probabilities concerning the different types of
infection, with b1(a):b2(a):b3(a)=1:0.7:0.05. I.e. the more severe
the disease the higher the probability of transmission. Further-
more, we assumed that the transmission probability depends on
the age of the susceptible individual. The age-specific transmis-
sion parameters were estimated from the estimated age specific
FOI, the contact matrix and the age specific steady state
prevalence. Ergo, the transmission coefficients were used to
calibrate the model on the assumed age-specific steady state
prevalences.
Figure 1. Schematic representation of the possible pathways within the pertussis DES (Discrete Event Simulation) model. Red circles
and red lines indicate events and pathways associated with vaccination, respectively; dashed circles indicate events where no time is actually
involved; and shaded circles indicate events where resources are consumed and therefore costs are included.
doi:10.1371/journal.pone.0013392.g001
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The exact duration of immunity acquired by natural infection is
not known. A recent review on the duration of immunity after
natural infection revealed estimates of protection varying from 4 to
20 years [13]. Accordingly, we considered two scenarios that differ
in the duration of immunity after a natural pertussis infection. In
scenario 1 we assumed that immunity on average wanes after 15
years (Rn=15), where individuals were fully and partially
protected for 2 and 13 years, respectively. In scenario 2, we
assumed that immunity on average wanes after 8 years (Rn=8),
where individuals were fully and partially protected for 2 and 6
years, respectively. The duration of immunity acquired by
vaccination did not differ between both scenarios at 8 years.
For both scenarios the situation in which a pertussis adolescent
booster vaccination would be implemented was compared to the
current situation without adolescent booster vaccination. Simula-
tions were performed for a population of 150,000 individuals with
a uniform age distribution (i.e. the age classes were equally sized).
The population size was stabilized with newborns who enter the
model exactly balancing the people who leave the model due to
death. Type 1 mortality was assumed as this is generally a
reasonable approximation for developed countries [20]. In
particular, we assumed that everybody lives to 75 years of age
and dies thereafter.
To mimic reality, at the start of the simulation (t=0) a booster
vaccination at the age of 4 years is implemented in the model.
Subsequently, for assessing the impact of an adolescent booster
dose, after 10 years (t=10) an extra vaccination at the age of 12
years is implemented in the model. Hereafter, a period of another
15 year was chosen for analyzing the impact of the adolescent
booster vaccination on the pertussis incidence and prevalence in
the population. This means that a total time horizon of 25 years
was used. Obviously, when assessing the outcomes over 25 years
of the current situation, no booster vaccination at t=10 was
implemented in the model. The parameter values used in the
stochastic model for both scenarios are shown in Table 1. Because
the model is stochastic, multiple simulation runs were performed
for both scenarios in order to capture the uncertainty in the
results.
Economic Model
The output of the dynamic model, in terms of annual primary,
recidive and asymptomatic infections, was used to estimate the
economic consequences of the implementation of the adolescent
booster vaccination program. In particular, the different types of
infections were linked to associated resource use and subsequent
costs. We considered the following costs: (i) vaccination costs (i.e.
vaccine price and administration costs); (ii) direct medical costs
associated with diagnosis, therapy and possible length of hospital
stay; and (iii) indirect costs due to productivity losses. All costs were
reported in J’s at 2008 price levels. If there were no cost estimates
available for 2008 we converted them to 2008 prices using gross
domestic product deflators [36].
The vaccination costs included the vaccine price and the
administration costs. One dose of the acellular pertussis vaccine
registered for the use in infants costs J18.30 [37]. As the price for
the accellular adolescent booster vaccine was not available at that
time we assumed a price of J18.30 for the adolescent booster
vaccine as well. Furthermore, the vaccine administration costs
were assumed at J6. Summarizing, the total vaccination costs
aggregated at J24.30 per individual.
The direct medical costs included costs associated with
diagnostic procedures, antibiotic treatment and hospital stay. We
assumed that these direct medical costs differ between notified and
unnotified cases. For estimating the age specific proportion of
notified cases per type of infection (i.e. I1,I 2 and I3) the age specific
steady state ratios I1:I2:I3 (where underreporting was taken into
account) together with the age specific notification data (from 1996
to 2000) were used. First, we assumed that notified persons
suffered from a primary pertussis infection. Subsequently, if the
incidence of notified cases exceeded the incidence of primary
infections, the remainder was assumed to suffer from a recidive
infection. Obviously, all asymptomatic infections were assumed to
be unnotified. The age- and infection-type specific reporting rates
Table 1. Variables used for both scenarios in the epidemiologic discrete event simulation model.
Variable Value Probability* (daily) References
Infectious period
I1 4 weeks 0.035 Expert panel
I2 3 weeks 0.047 Expert panel
I3 1 week 0.133 Expert panel
Loss of immunity
Scenario 1
Loss of full immunity rate after infection 2 years 0.00137 Expert panel, [13,14]
Loss of partial immunity rate after infection 13 years 0.00021 Expert panel, [13,14]
Loss of full immunity rate after vaccination 2 years 0.00137 Expert panel, [13,14]
Loss of partial immunity rate after vaccination 6 years 0.00046 Expert panel, [13,14]
Scenario 2
Loss of full immunity rate after infection 2 years 0.00137 Expert panel, [13,14]
Loss of partial immunity rate after infection 6 years 0.00046 Expert panel, [13,14]
Loss of full immunity rate after vaccination 2 years 0.00137 Expert panel, [13,14]
Loss of partial immunity rate after vaccination 6 years 0.00046 Expert panel, [13,14]
*The daily probability for an individual to lose infectiousness or immunity.
The expert panel consisted of: M. Kretzschmar, J.F.P. Schellekens, F.G.A. Versteegh, J.J. Roord and J.T. Poolman.
doi:10.1371/journal.pone.0013392.t001
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infection-type specific hospitalization rates were estimated using
data on pertussis related hospital admissions obtained from the
Dutch Prismant-database [38]. The estimation procedure of the
hospitalization rates was similar to that of the reporting rates; we
assumed that hospitalized persons suffered from a primary
pertussis infection and, if the incidence of hospitalizations
exceeded the incidence of primary infections, the remainder was
assumed to suffer from a recidive infection.
The exact hospitalization rates are shown in Appendix S1
(Table C1). Furthermore, national data on pediatric intensive care
stays revealed that 5.93% and 1.82% of the pertussis related
hospital admissions lead to intensive care stays for infants at the
age of 0 and 1 years respectively (data obtained from the national
PICU registry). The age-specific mean lengths of stay of the
pertussis-related hospital admissions are shown in Appendix S1
(Table C2). The average costs of a pediatric intensive care stay
were assumed at J5000 per admission plus an extra cost of J1500
per day (data obtained from the VU University Medical Centre in
Amsterdam, the Netherlands). The average daily costs for a
regular (i.e. standard care) stay were estimated at J367 [39].
Of the notified pertussis cases who were not hospitalized a
certain fraction was assumed to be treated ambulatory by a
medical specialist (e.g. pediatrician or lung specialist). As young
infants and elderly are most likely to be treated ambulatory we
assumed that these fractions were age dependent (Appendix S1;
Table C3). Resources used by all persons treated in or admitted to
the hospital were assumed to include: (i) 2 diagnostic laboratory
tests (which contained 1 polymerase chain reaction (PCR) test and
1 serology test); (ii) chest radiography; (iii) CRP (C-reactive
protein); (iv) blood concentration determination (e.g. leukocyte
count); and (v) antibiotic treatment with azithromycin. We
assumed that those persons additionally had on average one
general practitioner (GP) visit and three specialist visits. Further-
more, the remainder of the notified cases was assumed to incur 2
GP visits together with one course of azithromycin treatment. For
those we assumed that 83%, 4% and 13% were diagnosed by
means of serology, culture and PCR (data obtained from
Infectious Diseases Laboratory Groningen, the Netherlands). All
medical costs are shown in Table 2.
Our analysis was performed using the societal perspective; both
the direct medical costs (irrespective of reimbursement issues) and
the indirect costs of production losses were included in the analysis.
Tormans et al reported, based on replies from pediatricians, that
one of the parents would be absent of work for approximately 10
days while a child was suffering from pertussis [40]. We used this
estimate for children below the age of one, irrespective of infection
type and notification status. Conservatively, the mother was
assumed to care for the child (or adolescent). Moreover, in general,
if a person is hospitalized, the mean length of stay period was
added to the estimate. However, we did not include productivity
losses for children aged 0 to 3 months because of the maternity
leave entitled to new mothers. For notified children aged 1 to 9
years we assumed a work absence of 6 days by one of the parents
as reported by Lee et al [41]. For this group (and adolescents and
adults) we assumed that unreported cases result in half of the
productivity losses. The time missed from work due to a pertussis
infection in adolescents and adults has been estimated by Lee et al
[9]. For adolescents (10–19 years) they estimated a mean work loss
of 1.03 days for one of the parents. However, for adolescents aged
15 to 17 years we assumed a work loss of 2.65 days for those
adolescents that work themselves [9]. Finally, we assumed that
adults miss a mean of 5.98 days of work [9]. Note that we did not
distinguish productivity losses between primary and recidive
infections as the estimates extracted from the literature apply to
reported cases regardless of infection type [9,40,41]. Obviously, we
did not include productivity losses for asymptomatic infected
persons in the analysis.
Subsequently, the friction cost method was used to monetarily
value the indirect costs [42,43]. Here, we took both the national
unemployment and the elasticity of absence from work related to
productivity (i.e. 0.8 for the Netherlands) into account [39,44]. All
age-specific estimates of productivity losses and associated indirect
costs are shown in Table 3.
Cost-Effectiveness Analysis
The incremental cost-effectiveness was estimated for of a
pertussis booster vaccination program aimed at adolescents
compared to the current situation (i.e. no adolescent pertussis
vaccination). Cost-effectiveness was expressed as net costs per
quality adjusted life year (QALY). Hence, we linked quality
weights to the complications related to pertussis infections. Most of
the utilities used here were extracted from the only published study
on preferences in adults or parents of children with pertussis illness
[45]. If no utilities were available, reasonable figures were assumed
(Table 4). In the baseline analysis, we assumed that hospitalized,
reported and unreported cases suffer from severe cough, moderate
cough and mild cough, respectively. Pertussis illness in infants aged
,1 years of age was always assumed severe. Estimates for the
mean durations of pertussis illness were obtained from available
data [45,46]: (i) 80 days for infants aged ,1 year; (ii) 56 days for
children aged 1–9 years; (iii) 74 days for adolescents; and (iv) 87
days for adults. As the severity of pertussis disease wanes over time
we assumed that adults did not have be off work the full period,
either to take care of their ill child or because of their own illness.
Consequently, the full period over which quality of life losses occur
Table 2. Direct medical costs used as inputs for the economic
model (2008 euros).
Variable Costs References
Diagnostic procedures
Chest radiography 48.49 [39]
C-reactive protein 6.09 [38]
Blood concentration determination 9.74 [38]
PCR 99.13 [38]
Serology 43.38 [38]
Culture 15.00 [38]
Treatment
Azithromycine for adolescents and adults 8.20 [37]
Azithromycine for infants ,12 yrs 2.44/kg* [37,42]
Prescription fee (pharmacist) 6.10 [37]
Consult general practitioner 21.75 [39]
Consult medical specialist 52.89
# [39]
Hospital stay
Standard care day 387.75 [39]
Pediatric intensive care day 1500 [hospital
{]
Pediatric intensive care admission costs (one-off) 5000 [hospital
{]
{VU University Medical Centre Amsterdam, Netherlands.
*We calculated age-specific costs by using national data on age-specific
weights [39].
#A consult was assumed to last 30 minutes.
doi:10.1371/journal.pone.0013392.t002
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Dutch guidelines future health outcomes and future costs were
discounted at 1.5% and 4%, respectively [47].
Sensitivity analysis
To further test the robustness of the outcomes we performed a
univariate sensitivity analysis on various parameters in the
economic model. For example, the inclusion of universal pertussis
vaccination in the Dutch national immunization program would
probably result in a decline in vaccine price due to large scale
purchase. Therefore, we estimated the cost-effectiveness with a
vaccine price of J10 instead of J18.30 used in the baseline
analysis.
As, to our knowledge, only one study explicitly measured the
decrease of quality of life due to pertussis disease, we varied this
parameter in sensitivity analysis [45]. Here, we assessed the effect
on the outcomes if the quality weights were both decreased and
increased by 10%.
Furthermore, we investigated the effect of varying work loss on
the cost-effectiveness. Firstly, we estimated the effect of a 10%
increase and 10% decrease on the results. Furthermore, we
assessed the cost-effectiveness when the indirect costs were fully
omitted from the analysis.
Finally, we explored the impact of different discount rates on the
outcomes. In particular, health outcomes were discounted at a rate
of 4% according to the former Dutch guidelines for pharmacoe-
conomic research [48]. Furthermore, the effect of no discounting
for both costs and health outcomes was investigated.
Results
Figure 2 shows the estimated age-dependent FOI. The FOI is
estimated to be low in the very young age classes and it reaches a
peak in adults after which it decreases again in the oldest age
classes. This indicates that adults are at the highest risk of
acquiring a pertussis infection. Quantitatively, as the period of full
immunity after either vaccination or natural infection is similar in
both scenarios (i.e. 2 years), the age-dependent FOI is equal for
both scenarios investigated.
The implementation of an adolescent pertussis booster vacci-
nation program (technically, at t=10) reduces the absolute
incidence of all infection types (I1,I 1 and I3) in the total population
as shown in Figure 3. In particular, the figure represents the mean
outcomes for the scenario where natural immunity is assumed to
wane over 15 years. The decreasing trend in incidence is also
observed for the other scenario with 8 years of protection (not
shown). Note that although the overall incidence in the population
was equal in the steady situation for both scenarios, the difference
in duration of immunity led to different steady state ratios of
I1:I2:I3 (i.e. the ratio of symptomatic versus asymptomatic cases
differed in both scenarios). The relative decrease in incidence is
most apparent for primary pertussis infections. Furthermore, note
the relative large decrease in primary infections due to the booster
vaccination at the age of 4 years (technically, implemented at
t=0). The age-specific outcomes per infection type are shown in
Table 5. Highest percentage reductions in symptomatic infections
(i.e. I1 and I2) are seen in the adolescent age groups (i.e. 10–19
years) and in younger age groups (i.e. 4–9 years) for I3. For infants
aged below 1 year, 10–20% of primary infections is estimated to
be averted. Although the total number of recidive infections
declines due to adolescent booster vaccination, the incidence in the
older age classes increases slightly. Ergo, adolescent vaccination
causes a relative slight age shift for recidive infections.
Table 3. Productivity losses (days) and associated indirect
costs (J2008) per pertussis case.
Age* Hospitalized Costs Reported Costs Unreported Costs
0–3 m 00 0 0 00
3–11 m 17.98 1095 10.00 609 5.00 304
1y r 10.05 612 6.00 365 3.00 183
2 yrs 9.80 597 6.00 365 3.00 183
3 yrs 9.36 570 6.00 365 3.00 183
4–9 yrs 10.08 523 6.00 311 3.00 156
10–14 yrs 5.32 276 1.03 53 0.52 27
15–17 yrs 7.15 146 2.65 54 1.33 27
18–19 yrs 10.48 213 5.98 122 2.99 61
20–24 yrs 10.68 217 5.98 122 2.99 61
25–34 yrs 10.68 875 5.98 490 2.99 245
35–44 yrs 10.68 988 5.98 553 2.99 277
45–54 yrs 10.68 1004 5.98 562 2.99 281
55–64 yrs 10.68 713 5.98 399 2.99 200
65+ yrs 00 0 0 00
*For children aged 0 to 14 years the productivity losses refer to the mother.
doi:10.1371/journal.pone.0013392.t003
Table 4. Age-specific decrements in utility related to
pertussis illness.
Age Mild cough Moderate cough Sever cough
0 yr - - 0.42 [46]
1–3 yrs 0.20 [Assumed] 0.28 [Assumed] 0.39 [Assumed]
4–9 yrs 0.175 [Assumed] 0.25 [Assumed] 0.36 [Assumed]
10–17 yrs 0.15 [Assumed] 0.22 [45] 0.33 [46]
18–59 yrs 0.10 [46] 0.15 [45] 0.19 [46]
60+ yrs 0.10 [46] 0.15 [45] 0.19 [46]
References are given between brackets.
doi:10.1371/journal.pone.0013392.t004
Figure 2. Age-dependent force of infection (FOI) estimated
from the Dutch 1996–2000 pertussis incidence data.
doi:10.1371/journal.pone.0013392.g002
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PLoS ONE | www.plosone.org 6 October 2010 | Volume 5 | Issue 10 | e13392Figure 3. Absolute number of pertussis cases (incidence) for a population 150.000 persons after implementation of booster
vaccination at the age of 4 years (t=0) assuming natural immunity wanes after 15 years. The situation with adolescent vaccination at
t=10 and the current situation without adolescent vaccination are represented by the red and blue lines, respectively. I1=primary infection,
I2=recidive infection, I3=asymptomatic infection and Total=I1+I2+I3. Note the different scales of the y-axis for each infection type.
doi:10.1371/journal.pone.0013392.g003
Table 5. Mean differences* in absolute incidence numbers between the current situation and the situation with adolescent
pertussis booster vaccination over a 25 year period for a population of 150,000 people (percentage reductions between brackets).
Age Rn=8 years Rn=15 years
I1 I2 I3 I1 I2 I3
0 yr 3 (12%) <0 <0 4 (18%) <0 <0
1–3 yrs 10 (3%) 19 (5%) 55 (6%) 17 (10%) 22 (6%) 74 (8%)
4–9 yrs 33 (12%) 476 (14%) 1283 (15%) 39 (14%) 523 (17%) 1555 (19%)
10–19 yrs 140 (41%) 7455 (29%) 6540 (11%) 143 (41%) 6040 (32%) 9436 (14%)
20–49 yrs <0 21185 (23%) 6752 (2%) <0 21016 (25%) 7646 (3%)
50–74 yrs 0** 2385 (21%) 4158 (2%) 0** 2372 (22%) 5354 (3%)
Rn=loss of immunity after natural infection.
I1=primary infection, I2=recidive infection and I3=asymptomatic infection.
<0 refers to the situation where: 21.00,incidence,1.00.
Negative numbers indicate an increase in incidence numbers as a result of adolescent vaccination.
*Due to the extensive running time of the model_related to the high complexity_only 20 runs per scenario were performed.
**No I1 exists anymore beyond 50 years of age.
doi:10.1371/journal.pone.0013392.t005
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tation of an adolescent pertussis vaccination program are shown in
Table 6, in terms of costs and health gains. The indirect costs due
to productivity losses comprise by far the largest part of the costs
associated with pertussis diseases. Specifically, the indirect costs
show an increase in the older age groups (i.e. age $20 years) as a
result of the adolescent pertussis vaccination. Furthermore, the
vaccination costs over a 15-year period are estimated at J540.000.
Consequently, the incremental cost-effectiveness of adolescent
pertussis vaccination is estimated at J4418/QALY (range: 3205–
6364 J per QALY) and J6371/QALY (range: 4139–9549 J per
QALY) for the scenario with 8 and 15 years protection after
natural infection, respectively.
Finally, table 7 presents the results of the univariate sensitivity
analysis. Except a 10% increase in quality weights, changes
adopted in the cost- en health-related parameters had limited
effect on the cost-effectiveness.
Discussion
In this paper we present the first dynamic individual-based
approach to model pertussis transmission in the population.
Furthermore, we applied this model to estimate the cost-
effectiveness of a universal adolescent booster vaccination program
for the Dutch situation. Until now, almost all cost-effectiveness
analyses of pertussis vaccination programs previously performed
use standard decision analytic models to assess the effects of
vaccination [40,46,49–62]. However, as pertussis is a transmissible
infectious disease, a dynamic model is required to fully take into
account the spread of the disease over time in the population
[20,63]. Although van Boven et al [23,64] and Hethcote [65–69]
used a dynamic approach to model pertussis transmission, these
models were not used for economic analyses. So far, only
Edmunds et al [70] designed a dynamic model to estimate the
cost-effectiveness of pertussis booster vaccination in England and
Wales. Our model differs from the dynamic models designed by
van Boven, Hethcote and Edmunds in that those models are
deterministic and population-based whereas ours is stochastic and
individual-based [23,64–70].
In general, reliable and currently valid pertussis related FOI
estimates are difficult to obtain. Previously used estimates are
mostly based on incidence data from England and Wales before
the introduction of widespread vaccination [20,65,71]. These
estimates may however not describe the current situation in the
Netherlands. Moreover the methods used to estimate these age-
specific FOIs has a number of drawbacks as described by van
Boven et al [23]. As van Boven et al attempted to overcome these
drawbacks in their approach, we used the method they [23]
developed to consistently take the waning of immunity and
different types of infection into account to estimate age-specific
FOIs for the Dutch situation. We note that, unlike the stochastic
individual-based dynamic framework to model the pertussis
transmission in the population, the approach used to estimate
the age-specific FOIs was deterministic. However, as the structure
of both models and the parameter values used, after converting
from rates to probabilities, were similar, we felt this approach
could be justified.
The FOI estimated in this study differs from those previously
estimated for the Netherlands and England and Wales in terms of
both magnitude and shape [20,23,65,71]. The age-specific FOIs
estimated in this study are consistently higher than those estimated
by Grenfell and Anderson [71] and van Boven et al [23]. This is
due to the fact that we, contrary to others, corrected the incidence
numbers for occurrence of asymptomatic infections and underre-
porting. Consequently, the number of infectious people in the
Table 6. Mean age-specific outcomes* in terms of costs and QALYs. Absolute differences between current situation and the
situation with adolescent pertussis booster vaccination over the 25 year period for a population of 150,000 people.
Age Rn=8 years Rn=15 years
Direct medical costs (J) Indirect costs (J) QALYs Direct medical costs (J) Indirect costs (J) QALYs
0y r 10,786 1612 0.23 12,378 1651 0.41
1–3 yrs 601 4613 1.04 1586 8380 1.84
4–9 yrs 669 77,474 8.86 740 86,645 9.83
10–19 yrs 737 275,300 137.76 780 138,976 112.25
20–49 yrs 2127 2281,796 225.23 248 2271,117 221.21
50–74 yrs 242 256,864 28.00 277 248,103 27.74
Total 12,624 20,339 114.65 15,360 283,568 95.38
Negative numbers indicate an increase in costs or a decrease in QALYs as a result of adolescent vaccination.
*Due to the extensive running time of the model_related to the high complexity_only 20 runs per scenario were performed.
Rn=loss of immunity after natural infection.
doi:10.1371/journal.pone.0013392.t006
Table 7. Outcomes of the univariate sensitivity analysis.
Rn=8 years Rn=15 years
ICER (costs/QALY) ICER (costs/QALY)
Baseline Analysis 4418 6371
Vaccine price J10 1649 3043
Quality weights 210% 2338 3387
Quality weights +10% 31,797 40,955
Productivity losses 210% 4436 6284
Productivity losses +10% 4400 6459
No productivity losses 4595 5495
Discount rate health 4% 5224 7415
No discounting 5162 7887
Rn=loss of immunity after natural infection.
ICER=incremental cost-effectiveness ratio.
QALY=quality adjusted life year.
doi:10.1371/journal.pone.0013392.t007
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which susceptibles would acquire infection. Furthermore, the
difference in shape can be explained by different levels of
underreporting for different age-classes [33]. In particular, the
underreporting rate is much higher in the older age-classes
compared to infants.
According our DES-model, the incremental cost-effectiveness of
adolescent pertussis booster vaccination is estimated below
J10,000 per QALY for both scenarios investigated and in a wide
range of sensitivity analyses. The cost-effectiveness would be
slightly more favorable if the duration of immunity after natural
infection is 8 years (ICER: J4418 per QALY) compared to 15
years (ICER: J6371 per QALY). This is mainly due to the greater
amount of QALYs that can be gained by vaccination when the
duration of immunity after natural infection is ‘‘only’’ 8 years.
Obviously, the shorter the duration of immunity after natural
infection (i.e. the faster one becomes susceptible again), the higher
the risk of acquiring a symptomatic infection will be. In particular,
more recidive infections and associated quality of life loss can be
averted in the individuals aged 10–19 years old.
Although adolescent vaccination leads to a decrease in total
incidence of pertussis in the population, it caused an increase in
absolute numbers of recidive infections in the older age groups
(.20 years). Consequently, the total indirect costs increased as a
result of adolescent vaccination because the productivity losses are
highest in these age classes. Furthermore, the direct medical costs
also increased in adults due to the increase in recidive infections in
these individuals. This particularly stresses the importance of using
a dynamic approach instead of a static one when estimating the
cost-effectiveness of pertussis booster vaccination strategies as static
models are not able to predict these age shifts. Obviously, the age
shift modeled here slightly worsens the cost-effectiveness of
adolescent vaccination. Although it is often thought that the
inclusion of herd-immunity effects can only have beneficial effects,
they can be detrimental as well, as previously also noticed by
Brisson et al [72].
Here, we will discuss a possible explanation for the increase in
recidive infections in adults. First, the total incidence in the
vaccinated age groups will decrease as a result of vaccination.
Subsequently, this will lead to a decrease of the infection pressure
in the population (i.e. the probability of contacting an infectious
individual will decrease). Ergo, the probability of becoming
susceptible again will increase for individuals. Consequently, the
ratio of symptomatic versus asymptomatic cases will change in
favor of the symptomatic cases. Accordingly, although the total
incidence decreased, in this analysis, under these baseline
assumptions, this resulted in an absolute increase of symptomatic
cases in the adult groups. However, the exact effects of adolescent
vaccination on the relative and absolute incidences will obviously
depend on the underlying assumptions. For example, assuming no
infectiousness for asymptomatically infected persons could possibly
result in an unintended increase of incidence in young infants if the
absolute number of symptomatic cases increases in adults.
However, on the contrary, the cost-effectiveness could possibly
become more favorable if the infectiousness of asymptomatic cases
is increased relatively to that of symptomatic cases. This is
certainly an area for further research.
Univariate sensitivity analyses revealed that varying discount
rates and parameters associated with cost measures had limited
effect on the cost-effectiveness. Regarding quality of life measures
only an increase of 10% in the quality weights for pertussis illness
showed a considerable effect (i.e. increase) on the ICER.
However, such a large increase in quality weights would be
rather unrealistic as the increased weights, especially in adoles-
cents and adults, approach one (i.e. perfect health) which would
mean that pertussis illness would hardly influence the quality of
life of an individual.
All previously performed cost-effectiveness analyses using a
static approach showed potential favourable cost-effectiveness for
adolescent pertussis booster vaccination [49,59,60,61,73]. Isked-
jian et al [59] even estimated that vaccination of 14-year old
adolescents in Ontario (Canada) could be a cost-saving strategy
from a societal viewpoint. However, these studies were not able to
fully capture the herd-immunity effects as that would require a
dynamic approach. The only cost-effectiveness analysis based on a
dynamic model, performed by Edmunds et al [70], reported more
reserved conclusions. In particular, they estimated that the
introduction of a booster at 4 years is possibly more cost-effective
than the implementation of an adolescent vaccination program in
the UK [70]. This immediately stresses another difficulty in
comparing the outcomes of different cost-effectiveness analyses.
The effects of adolescent booster vaccination on the epidemiology
and cost-effectiveness will differ among different countries as there
is a lot of variability in national vaccination policies [1,74]. For
example, in the Netherlands booster vaccination for 4-year olds
was indeed actually recently introduced and was present in all our
strategies, rather than serving as an alternative. Furthermore, it
depends on the exact organization of the current national
immunization schedule what will be the best timing of vaccinating
adolescents.
There are several limitations of our study. The main
disadvantage of the current version of the model is the running
time. Although ideally one wants, to fully capture all variability in
the outcomes, to run a stochastic model many (e.g. 10,000) times,
this was not fully possible here within a reasonable time.
Consequently, we were able to run the model only a few times.
However, this limited number of replications also already shows
insight in the uncertainty surrounding the cost-effectiveness. In this
situation (i.e. 20 runs per scenario) the incremental cost-
effectiveness never exceeded the J10,000 per QALY for both
scenarios which makes it plausible that the expected cost-
effectiveness is very likely below this value.
Also, deaths from pertussis were conservatively not taken into
account as on average less than one death per year was reported
over the last decade in the Netherlands [44]. However, from other
countries we do know that there is potential underreporting of
pertussis related deaths [75,76]. Although different national
surveillance systems are often not comparable, underreporting of
deaths probably also exists in the Netherlands. This is because of
the difficulty in defining pertussis as the cause of death. People
often decease as a result of the complications (e.g. pneumonia)
which will be reported as the cause of death, with the underlying
pertussis disease being missed. The inclusion of pertussis related
deaths would probably lead to a slightly more favourable cost-
effectiveness as adolescent vaccination is estimated to slightly
decrease the incidence in the most vulnerable group (i.e. young
infants). However, if, on the other hand, unreported deaths more
often occur in adults, the inclusion of this underreporting in
mortality could lead to less favourable cost-effectiveness
Furthermore, we did not take side effects of the booster vaccine
into account. However, the inclusion of side effects will probably
not result in a significant increase in the cost-effectiveness as
acellular pertussis vaccines for adolescents are generally charac-
terized as safe [29,31]. In clinical trials no significant differences in
systematic symptoms between placebo and vaccine groups were
noted [29,31]. Although local reactions can occur, these would not
incur any considerable costs or quality of life loss.
Pertussis Vaccination
PLoS ONE | www.plosone.org 9 October 2010 | Volume 5 | Issue 10 | e13392Finally, we used incidence data from 1996–2000 to obtain age-
specific steady state incidences, which are required in order to
discard the time dependence in the incidence and prevalence.
Although we are fully aware of the fact that this period did not
reflect an endemic equilibrium in reality, we could not neglect the
clear increase in incidence numbers from 1996 onwards.
Furthermore, data from 2001 onwards was not included as since
the start of that year pertussis booster vaccination for 4-year olds
has been introduced in the Netherlands. Ergo, we believe that our
approach is most optimal in the current circumstances. Unfortu-
nately we are not able to reliably predict the implications of this
assumption on the cost-effectiveness. To do so, the exact cause of
the rise in incidence numbers from 1996 has to be known in order
to precisely model this increase.
In this analysis we estimated the cost-effectiveness of an acellular
pertussis booster vaccine for adolescents. However, in practice the
formulation given can also contain diphtheria and tetanus toxoids
(dTpa vaccine) [77]. The cost-effectiveness of this combination
vaccine could differ from the cost-effectiveness of a single acellular
pertussis booster vaccine. Whether or not this combination vaccine
will be more cost-effective depends on whether the extra costs
outweigh the extra benefits by preventing diphtheria and tetanus
as well. To fully and appropriately evaluate the health economic
consequences of this combination vaccine all three diseases should
be taken into account in the model.
Ideally, a health-economic model is generalisable from one
country to the other. Our model can be applied to other countries,
however several complicating factors have to be taken into
account. In particular, as our model is for an infectious disease,
local and national transmission patterns are of importance and the
model should be adapted accordingly to such patterns that will
differ from the Dutch situation applied in this analysis.
Furthermore, national vaccination schedules and exact types of
pertussis vaccines used may differ, for example, regarding the
number of components included, specific brands and formulations.
Obviously, efficacies of different schedules, combinations and
brands may differ. For example, Jefferson et al [27] showed that
the vaccine effectiveness of vaccines measured in children varied
considerably from manufacturer to manufacturer. Taking such
differences between countries adequately into account would allow
our modelling to be extended to other countries. Initiatives for
such further work are indeed currently undertaken.
Conclusion
In conclusion, we designed a dynamic individual-based DES-
model to model pertussis transmission in the population in order to
estimate the cost-effectiveness of universal booster vaccination
strategies. As also holds true for other infectious diseases, to
appropriately asses the cost-effectiveness of pertussis vaccination
inclusion of herd-immunity effects is crucial as vaccination
considerably reduces the transmission in the population. We have
shown that adolescent booster vaccination is likely to be a cost-
effective intervention for the Dutch situation, as in the Netherlands
interventions are certainly considered cost-effective if cost-
effectiveness is estimated below a threshold of J 20,000 per
QALY [78]. However, to make a through-out decision about the
implementation of such a pertussis booster vaccination strategy,
one should first compare the cost-effectiveness of the adolescent
vaccination with that of other vaccination strategies (e.g. adult
vaccination or cocooning). This further stresses the reason for
developing an individual based model. As a next step a social
network can be easily included to appropriately model household
contacts in order to accurately estimate the cost-effectiveness of a
cocooning strategy. Currently, mixing is only based on age. The
main disadvantage of the model is the considerable running time,
which made it impossible to run hundreds of simulations.
Currently, we are programming the model in another computer
language in order to try to speed up the modeling process.
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